فارسی
The FDA’s approval today signifies a major advancement in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Breyanzi, a groundbreaking CAR-T therapy, has received its second approval, this time for its efficacy in CLL and SLL treatment. This approval is based on compelling data from clinical trials, notably the TRANSCEND CLL 004 study, which showcased an impressive 20% complete response rate.
This marks a pivotal moment as Breyanzi initially gained FDA approval in June 2022 for the treatment of large B-cell lymphoma, a subtype of non-Hodgkin lymphoma known for its rapid growth. Today’s approval solidifies its standing as a versatile treatment option, now extending its reach to CLL and SLL, both of which affect lymphocytes.
Bristol Myers Squibb’s Breyanzi has thus expanded its scope to encompass various types of blood cancers, thanks to these CAR-T approvals. This expansion represents a significant stride forward in the realm of treatment options available to patients, underscoring the continual progress in the fight against cancer.
